Vaccines are biological substance that protect humans from infections caused by bacteria and viruses. The different types of vaccines include live/attenuated vaccine, inactivated/killed vaccine, toxoid vaccine, and conjugate vaccine. Vaccines are administered through subcutaneous or intramuscular routes using a syringe or needle. Needle free technologies are one of the novel vaccine delivery technologies as they are effectively used in mass immunization programmes, thereby reducing the chances of needle stick injuries and the complications associated with the multiple use of single needle. Moreover, other vaccine delivery devices include disposable syringes, jet injectors, micro- needles, and intradermal delivery devices for delivery of inactivated poliovirus vaccine.
Rise in the adoption of needle free technology is expected to augment the growth of vaccine delivery devices market
The major factors contributing to the growth of vaccines delivery devices market are needle free delivery systems, as these systems have potential to decrease the dose of the vaccine antigen and also enhances the vaccine immunogenicity. Rapid advancement of technology in systematic delivery of vaccines such as micro-needles and electroporation, is expected to augment the growth of vaccines delivery devices market. Increasing use of micro-needles is attributed to the demand for the painless self-administration by the patients. Vaccines delivered through micro-needles into the dermis affects faster than the intra-muscular injections, augments the market growth. However, one of the major factors restraining the market growth is the cost of the micro-needles especially in the emerging countries.
Vaccine Delivery Devices Market Taxonomy
Vaccine delivery devices market can be segmented on the basis of product type, route of administration, end user and geography.
On the basis of product type, the global vaccine delivery devices market is segmented into
- Jet Injectors
- Micro needles
- Aerosol/dry powder inhalation
- Intranasal delivery devices
- Intradermal delivery devices
On the basis of route of administration, the global vaccine delivery devices market is segmented into
On the basis of end user, the global vaccine delivery devices market is segmented into
On the basis of geography, the global vaccine delivery devices markets can be segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global vaccine delivery devices, owing to the rising demand of intranasal delivery devices, which offers non-invasive route of administration as compared to injections. Thus, intranasal delivery devices increases the potential for patient compliance and creates a platform for the improvement in pharmacokinetics profiles. Moreover, rapid growth in immunization coverage due to financial support from the Bill & Melinda Gates Foundation and others in 2010, made vaccine available to millions of people in U.S. Furthermore, Asia Pacific is expected to be the key market for the vaccine delivery devices market over the forecast period, due to rising awareness regarding jet injector devices, which has reduced the high risk of cross contamination, needle stick injuries, and is less painful for the patient.
Innovation of hollow microstructured transdermal system, is expected to fuel the market growth
Some of the major players operating in the global vaccines delivery devices market include Panacea Pharmaceuticals, 3 M, Biojet Medical Technologies Pharmajet, Valeritas, Vaxxas, Gerresheimer, Schott AG, Corium International, and Becton Dickinson & Company. Various strategies are adopted by the key players to sustain their position in the market include product development, innovation, mergers and acquisition. For instance, 3M involved in the vaccines delivery devices market recently launched a new drug delivery device named 3M Hollow Microstructured transdermal System (hMts). This device directly delivers the vaccine to the patient’s dermis, which would give rise to the stronger immune response than traditional intramuscular injections. Also, hMTS facilitate consistent and reproducible delivery of the drug. Furthermore, 3M Company has collaborated with Panacea Pharmaceuticals in administering therapeutic cancer vaccine directly to the dermis through hMTS.